NLP-powered insights into cognitively impaired schizophrenia (CIAS) patients in UK secondary care
NLP-powered insights into cognitively impaired schizophrenia (CIAS) patients in UK secondary care
Partner: Global Pharma Company
FOCUS: Generate real-world evidence on CIAS – disease impact, patient pathways, and recruitment for research & treatment.
CHALLENGE
- Limited visibility of CIAS population in the UK
- Fragmented registry data and clinician estimates
- Underrepresented complexity (polypharmacy, comorbidities).
OUR APPROACH
- Used Akrivia’s RDLA platform and applied NLP to characterise CIAS population and subgroups.
OUTCOMES
- Deep cohort understanding
- Profiles of symptoms, functions and healthcare use
- Clear patient subgroups for research and intervention.
IMPACT
- Boosted confidence in next research steps
- Faster, lower-risk patient identification
- Reduced timelines and cost.
“Akrivia’s data-driven insights and lived-experience input gave us a clear roadmap for trial feasibility in TRS. Their approach transformed how we plan recruitment and patient engagement strategies.”
– Clinical Development Lead, Company X